The East London Parkinson Disease Project – engaging a diverse population in research
Objective: The objective of this study was to engage a diverse group of people with Parkinson disease (PwP) from East London and build a research…Priorities of PD patients for treatment of cognitive-driven ADL impairment
Objective: To define cognitive-driven impairments in activities of daily living (ADL) with high priority for rehabilitation ranked by Parkinson’s disease (PD) patients. Background: Impairments in…History of Comorbidities and their Association with Developing Cognitive Dysfunction in PD
Objective: To examine comorbidities associated with incident cognitive dysfunction in PD. Background: The risk of dementia is up to six-times higher in PD compared to…MRI to investigate cerebrovascular changes in Parkinson’s disease
Objective: To determine the value of MRI-derived cerebrovascular metrics and their relationship with global cognitive impairment in Parkinson’s disease (PD). Background: Cognitive impairment is a…A second level neuropsychological battery for Parkinson’s Disease. Normative data from the Italian population.
Objective: The main purpose of this work is to propose modern Italian co-normed data for a battery of ten widely used neuropsychological tests for Parkinsons’…Cognition in parkinson disease: Tunisian clinical experience
Objective: In this study, we identified among Parkinson Disease patients those pre-disposed to cognitive impairment, and described their clinical profiles. Background: Parkinson disease (PD) is…Impact of ApoE genotype on cognition in idiopathic and genetic forms of Parkinson’s disease
Objective: The aim of our current report was to assess the impact of Apolipoprotein-E (ApoE) genotype on cognition in idiopathic Parkinson’s disease (PD) patients and…MoCA and MMSE subitems’ sensitivity across the PD-cognitive spectrum
Objective: To determine which Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) subitems are more sensitive in detecting cognitive abnormalities in patients with PD…SelfCog®: a digitized cognitive battery to classify Parkinson disease (PD) patients with or without Mild Cognitive Impairment (MCI)
Objective: We tested the performance of the SelfCog® to classify PD patients as MCI. Background: MCI is a strong risk factor of dementia in PD…Plasma p-Tau181 and p-Tau231 in Parkinson’s Disease
Objective: To explore whether plasma phosphorylated tau (p-Tau) 181 and p-Tau231 levels are associated with cognition in a Parkinson’s Disease (PD) cohort. Background: We recently…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 117
- Next Page »